NO20075648L - Vaksinesammensetning - Google Patents

Vaksinesammensetning

Info

Publication number: NO20075648L
Authority: NO; Norway
Prior art keywords: vectors; adenoviruses; hiv; relates; methods
Prior art date: 2005-05-12

Application number

NO20075648A

Other languages

English (en)

Norwegian (no)

Inventor

Peter Franz Ertl

John Philip Tite

Cathrine Ann Van Wely

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-12

Filing date

2007-11-06

Publication date

2008-02-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075648(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-11-06 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-02-07 Publication of NO20075648L publication Critical patent/NO20075648L/no

Links

229960005486 vaccine Drugs 0.000 title 1
241000701161 unidentified adenovirus Species 0.000 abstract 4
239000013598 vector Substances 0.000 abstract 4
241000700605 Viruses Species 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000013603 viral vector Substances 0.000 abstract 2
241001217856 Chimpanzee adenovirus Species 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
241000990167 unclassified Simian adenoviruses Species 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Biochemistry (AREA)
Zoology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20075648A 2005-05-12 2007-11-06 Vaksinesammensetning NO20075648L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68038905P	2005-05-12	2005-05-12
PCT/EP2006/004854 WO2006120034A1 (fr)	2005-05-12	2006-05-10	Composition de vaccin

Publications (1)

Publication Number	Publication Date
NO20075648L true NO20075648L (no)	2008-02-07

Family

ID=36954770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20075648A NO20075648L (no)	2005-05-12	2007-11-06	Vaksinesammensetning

Country Status (20)

Country	Link
US (1)	US20090208515A1 (fr)
EP (1)	EP1880012B1 (fr)
JP (2)	JP5175178B2 (fr)
KR (1)	KR101451620B1 (fr)
CN (2)	CN101384722A (fr)
AR (1)	AR053275A1 (fr)
AU (1)	AU2006245920A1 (fr)
BR (1)	BRPI0608798A2 (fr)
CA (1)	CA2608316A1 (fr)
EA (1)	EA200702190A1 (fr)
ES (1)	ES2546330T3 (fr)
IL (1)	IL186828A (fr)
MA (1)	MA29458B1 (fr)
MX (1)	MX2007014038A (fr)
NO (1)	NO20075648L (fr)
PE (1)	PE20061372A1 (fr)
SG (1)	SG182173A1 (fr)
TW (1)	TW200716750A (fr)
WO (1)	WO2006120034A1 (fr)
ZA (1)	ZA200709518B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002365366B2 (en)	2001-11-21	2007-05-10	The Trustees Of The University Of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2008027394A2 (fr)	2006-08-28	2008-03-06	The Wistar Institute Of Anatomy And Biology	Construction permettant d'augmenter les réponses immunitaires
PL2137210T3 (pl) *	2007-03-02	2017-06-30	Glaxosmithkline Biologicals Sa	Nowy sposób i kompozycje
US9717788B2 (en)	2007-03-02	2017-08-01	Glaxosmithkline Biologicals Sa	Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008331905B2 (en) *	2007-11-28	2014-09-18	The Trustees Of The University Of Pennsylvania	Simian subfamily B adenovirus SAdV-28 and uses thereof
CN101883858B (zh)	2007-11-28	2015-07-22	宾夕法尼亚大学托管会	猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
JP5661476B2 (ja)	2008-03-04	2015-01-28	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
US9839684B2 (en)	2011-04-06	2017-12-12	Biovaxim Limited	Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
SI2825640T1 (sl)	2012-03-12	2016-08-31	Crucell Holland B.V.	Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
SG11201407343XA (en)	2012-05-18	2014-12-30	Univ Pennsylvania	Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US9624510B2 (en)	2013-03-01	2017-04-18	The Wistar Institute	Adenoviral vectors comprising partial deletions of E3
EP2970407B1 (fr) *	2013-03-14	2023-11-15	Amgen Inc.	Variants d'inhibiteur tissulaire de la métalloprotéinase type iii (timp-3), compositions et procédés
DK3271729T3 (da)	2015-03-18	2020-12-14	Janssen Vaccines & Prevention Bv	Analyser til rekombinante ekspressionssystemer
JP6735288B2 (ja)	2015-04-14	2020-08-05	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
BR112017026523A2 (pt) *	2015-06-12	2018-08-14	Glaxosmithkline Biologicals Sa	vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
US10343884B2 (en)	2015-07-10	2019-07-09	E. & J. Gallo Winery	System and method for dispensing a beverage
CN109154000B (zh)	2016-05-12	2022-07-05	扬森疫苗与预防公司	有效和平衡的双向启动子
RU2745500C2 (ru)	2016-06-20	2021-03-25	Янссен Вэксинс Энд Превеншн Б.В.	Эффективный и сбалансированный двунаправленный промотор
EP3490610A4 (fr)	2016-08-01	2020-05-20	The Wistar Institute Of Anatomy And Biology	Compositions et procédés de vecteurs adénoviraux à réplication déficiente pour des applications de vaccin
US11034978B2 (en)	2017-02-09	2021-06-15	Janssen Vaccines & Prevention B.V.	Potent and short promoter for expression of heterologous genes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998010087A1 (fr) *	1996-09-06	1998-03-12	Trustees Of The University Of Pennsylvania	Vecteurs d'adenovirus de chimpanze
US6733993B2 (en) *	2000-09-15	2004-05-11	Merck & Co., Inc.	Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
JP2004508064A (ja) *	2000-09-15	2004-03-18	メルク　エンド　カムパニー　インコーポレーテッド	コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
KR20040043129A (ko) *	2001-06-22	2004-05-22	더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지	세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
MXPA04002631A (es) *	2001-09-20	2004-07-08	Glaxo Group Ltd	Vacunas de adn optimizadas por codon gag-vih.
GB0225788D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
GB0225786D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
AU2004276559A1 (en) *	2003-09-24	2005-04-07	Oxxon Therapeutics Limited	HIV pharmaccines
GB2406336A (en) *	2003-09-24	2005-03-30	Oxxon Pharmaccines Ltd	HIV Pharmaccines
GB0417494D0 (en) *	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine

2006
- 2006-05-10 AR ARP060101875A patent/AR053275A1/es unknown
- 2006-05-10 ES ES06743016.5T patent/ES2546330T3/es active Active
- 2006-05-10 EP EP06743016.5A patent/EP1880012B1/fr active Active
- 2006-05-10 CA CA002608316A patent/CA2608316A1/fr not_active Abandoned
- 2006-05-10 CN CNA2006800162796A patent/CN101384722A/zh active Pending
- 2006-05-10 TW TW095116578A patent/TW200716750A/zh unknown
- 2006-05-10 KR KR1020077029093A patent/KR101451620B1/ko not_active Expired - Fee Related
- 2006-05-10 US US11/913,952 patent/US20090208515A1/en not_active Abandoned
- 2006-05-10 MX MX2007014038A patent/MX2007014038A/es active IP Right Grant
- 2006-05-10 BR BRPI0608798-1A patent/BRPI0608798A2/pt not_active IP Right Cessation
- 2006-05-10 PE PE2006000493A patent/PE20061372A1/es not_active Application Discontinuation
- 2006-05-10 JP JP2008510517A patent/JP5175178B2/ja not_active Expired - Fee Related
- 2006-05-10 EA EA200702190A patent/EA200702190A1/ru unknown
- 2006-05-10 WO PCT/EP2006/004854 patent/WO2006120034A1/fr not_active Ceased
- 2006-05-10 AU AU2006245920A patent/AU2006245920A1/en not_active Abandoned
- 2006-05-10 SG SG2012041687A patent/SG182173A1/en unknown
- 2006-05-10 CN CN2013100023418A patent/CN103088060A/zh active Pending
2007
- 2007-10-22 IL IL186828A patent/IL186828A/en not_active IP Right Cessation
- 2007-11-05 ZA ZA2007/09518A patent/ZA200709518B/en unknown
- 2007-11-06 NO NO20075648A patent/NO20075648L/no not_active Application Discontinuation
- 2007-11-20 MA MA30386A patent/MA29458B1/fr unknown
2012
- 2012-08-24 JP JP2012185395A patent/JP2013046613A/ja active Pending

Also Published As

Publication number	Publication date
TW200716750A (en)	2007-05-01
CN103088060A (zh)	2013-05-08
MA29458B1 (fr)	2008-05-02
WO2006120034A1 (fr)	2006-11-16
MX2007014038A (es)	2008-02-11
KR20080021659A (ko)	2008-03-07
WO2006120034A8 (fr)	2007-11-15
JP2013046613A (ja)	2013-03-07
ZA200709518B (en)	2014-01-29
KR101451620B1 (ko)	2014-10-21
EP1880012B1 (fr)	2015-07-08
EP1880012A1 (fr)	2008-01-23
SG182173A1 (en)	2012-07-30
EA200702190A1 (ru)	2008-04-28
IL186828A0 (en)	2008-02-09
ES2546330T3 (es)	2015-09-22
AR053275A1 (es)	2007-04-25
IL186828A (en)	2015-06-30
US20090208515A1 (en)	2009-08-20
AU2006245920A1 (en)	2006-11-16
PE20061372A1 (es)	2007-01-16
JP5175178B2 (ja)	2013-04-03
BRPI0608798A2 (pt)	2011-03-15
CA2608316A1 (fr)	2006-11-16
CN101384722A (zh)	2009-03-11
JP2008539746A (ja)	2008-11-20

Legal Events

Date	Code	Title	Description
2013-12-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20075648L (no)	2008-02-07	Vaksinesammensetning
NO20090194L (no)	2009-03-10	Rekombinant viral vaksine
Capone et al.	2006	A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques
Forrester et al.	2008	Recombination in rabbit haemorrhagic disease virus: possible impact on evolution and epidemiology
WO2008014521A3 (fr)	2008-12-24	Vaccins améliorés et leurs procédés d'utilisation
JP2009544333A5 (fr)	2011-09-01
BR112016020688A2 (pt)	2017-10-03	Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
JP2014534202A5 (fr)	2015-12-03
NZ616304A (en)	2016-01-29	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RU2019144161A (ru)	2021-08-05	Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
RU2015135890A (ru)	2017-03-27	Композиция вакцины
JP2016501015A5 (ja)	2017-07-27	デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
CY1109036T1 (el)	2014-07-02	Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
WO2011057254A3 (fr)	2011-08-18	Vaccins à base de vecteur adénoviral simien
TW200502246A (en)	2005-01-16	Vaccine
WO2008115314A3 (fr)	2009-10-15	Vecteur vaccinal flavivirus contre le virus de la grippe
EA200601043A1 (ru)	2006-10-27	Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара
WO2003076591A3 (fr)	2004-03-25	Compositions et procedes destines a produire une reponse immunitaire
CO6541529A2 (es)	2012-10-16	Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
D’Andrea et al.	2011	A detailed comparative analysis on the overall codon usage patterns in hepatitis A virus
WO2012042279A3 (fr)	2012-07-26	Compositions immunogènes de vecteur viral
AR067439A1 (es)	2009-10-14	Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
NO20045315L (no)	2004-12-03	Ekspresjon av gener i Modifisert Vacciniavirus Ankara ved a bruke kukoppe ATI-promoteren
WO2007015783A3 (fr)	2007-08-02	Nouvelles souches virales atténuées et leurs utilisations
WO2008127307A3 (fr)	2009-02-26	Induction d'une réponse immunitaire dirigée contre le virus de la dengue utilisant une approche « prime-boost »